Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study

References

• Langan S, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360.
   PubMed Web of Science ®Google Scholar
• Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014:354250.
   PubMedGoogle Scholar
• Kolb L, Ferrer-Bruker SJ. Atopic Dermatitis. StatPearls. August 2021; [cited 2021 Oct 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448071/.
   Google Scholar
• Holm J, Agner T, Clausen M-L, et al. Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30(10):1760–1767.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Silvaggio D, et al. Quality of life and psychological impact in patients with atopic dermatitis. J Clin Med. 2021;10(6):1298.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim BE, Leung DY. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc. 2019;40(2):84–92.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based european guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878.
   PubMed Web of Science ®Google Scholar
• Torres T, Ferreira EO, Gonçalo M, et al. Update on atopic dermatitis. Acta Med Port. 2019;32(9):606–613.
   PubMed Web of Science ®Google Scholar
• Renert-Yuval Y, Guttman-Yassky E. Systemic therapies in atopic dermatitis: the pipeline. Clin Dermatol. 2017;35(4):387–397.
   PubMed Web of Science ®Google Scholar
• Dattola A, Bennardo L, Silvestri M, et al. What’s new in the treatment of atopic dermatitis? Dermatol Ther. 2019;32(2):e12787.
   PubMed Web of Science ®Google Scholar
• Ratchataswan T, Banzon TM, Thyssen JP, et al. Biologics for treatment of atopic dermatitis: current status and future Prospect. J Allergy Clin Immunol Pract. 2021;9(3):1053–1065.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. DUPIXENT® (dupilumab): EPAR Product Information. Published 2021; [cited 2021 July 27]. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf.
   Google Scholar
• Food and Drug Administration. DUPIXENT® (dupilumab): highlights of prescribing information. Published June 2021.; [cited 2021 Oct 24]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761055s016lbl.pdf.
   Google Scholar
• Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11(5):467–474.
   PubMed Web of Science ®Google Scholar
• Rodrigues M, Nogueira M, Torres T. Dupilumab for atopic dermatitis: evidence to date. G Ital Dermatol Venereol. 2019;154(6):696–713.
   PubMed Web of Science ®Google Scholar
• Nettis E, Patella V, Lombardo C, et al. Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis. Allergy. 2020;75(10):2653–2661.
   PubMed Web of Science ®Google Scholar
• Nettis E, Ferrucci S, Ortoncelli M, et al. Use of dupilumab for 543 adult patients with Moderate-To-Severe atopic dermatitis: a multicenter, retrospective study. J Investig Allergol Clin Immunol. 2020;32(2):641.
   Web of Science ®Google Scholar
• Kreeshan F, Al-Janabi A, Warren R, et al. Real-World experience and laboratory monitoring of dupilumab in patients with moderate to severe atopic dermatitis in a tertiary Centre. Dermatol Ther. 2021;11(1):149–160.
   Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303.
   PubMed Web of Science ®Google Scholar
• de Bruin-Weller M, Thaçi D, Smith C, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin a or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–1101.
   PubMed Web of Science ®Google Scholar
• Simpson E, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
   PubMed Web of Science ®Google Scholar
• Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life french multicenter adult cohort. J Am Acad Dermatol. 2019;81(1):143–151.
   PubMed Web of Science ®Google Scholar
• Jang D, Heo S, Kook H, et al. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world . Sci Rep. 2021;11(1):23539.
   PubMed Web of Science ®Google Scholar
• Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol. 2021;35(4):958–964.
   PubMed Web of Science ®Google Scholar
• Sears A, Woolf R, Gribaleva E, et al. Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-Centre, prospective 1-year observational cohort study of the first 100 patients treated. Br J Dermatol. 2021;184(4):755–757.
   PubMed Web of Science ®Google Scholar
• Wang C, Kraus CN, Patel KG, et al. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients’ records. Int J Dermatol. 2020;59(2):253–256.
   PubMed Web of Science ®Google Scholar
• Olesen C, Holm J, Nørreslet L, et al. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral Centre. J Eur Acad Dermatol Venereol. 2019;33(8):1562–1568.
   PubMed Web of Science ®Google Scholar
• Hamilton J, Harel S, Swanson B, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915–931.
   PubMed Web of Science ®Google Scholar
• Ariëns L, van der Schaft J, Bakker D, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. Allergy. 2020;75(1):116–126.
   PubMed Web of Science ®Google Scholar
• de Wijs L, Nguyen N, Kunkeler A, et al. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2020;183(4):745–749.
   PubMed Web of Science ®Google Scholar
• Guenova E, Skabytska Y, Hoetzenecker W, et al. IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci USA. 2015;112(7):2163–2168.
   PubMed Web of Science ®Google Scholar